Responses
Late-breaking abstracts
Biomarkers, immune monitoring, and novel technologies
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Compose a Response to This Article
Other responses
No responses have been published for this article.